E3 PreliminaryModerate confidencePEM not requiredReview-NarrativePeer-reviewedMachine draft
Abnormal endogenous pain modulation is a shared characteristic of many chronic pain conditions.
Staud, Roland · Expert review of neurotherapeutics · 2012 · DOI
Quick Summary
People with chronic pain often have trouble turning off pain signals in their brain and spinal cord, even when they should. This review explains that many chronic pain conditions—including ME/CFS—share a common problem: their bodies amplify pain signals instead of suppressing them. Tests can measure how well someone's natural pain-blocking system works, and these tests might help predict who will develop chronic pain.
Why It Matters
This framework is important for ME/CFS because it positions abnormal pain processing alongside other chronic pain conditions, validating neurobiologic mechanisms in ME/CFS and suggesting that quantitative sensory testing could identify ME/CFS patients at high risk of worsening symptoms or treatment resistance. Understanding shared pain modulation defects across syndromes may identify transdiagnostic therapeutic targets and improve patient stratification.
Observed Findings
- Many chronic pain syndromes (fibromyalgia, temporomandibular joint disorder, irritable bowel syndrome, headache, chronic fatigue syndrome) demonstrate hypersensitivity to painful stimuli.
- Chronic pain patients show reduced endogenous pain inhibition compared to pain-free individuals.
- Pain inhibition capability is normally distributed across the general population and varies considerably among individuals.
- Temporal summation and conditioned pain modulation are measurable biomarkers of pain facilitation and inhibition, respectively.
Inferred Conclusions
- Abnormal endogenous pain modulation (both increased facilitation and decreased inhibition) is a shared characteristic of multiple chronic pain syndromes including ME/CFS.
- The capability to inhibit pain is a distributed trait in the population that may predict susceptibility to chronic pain development.
- Identifying individuals with impaired pain inhibition could enable early intervention and risk stratification for chronic pain conditions.
Remaining Questions
- Do prospective longitudinal studies confirm that baseline pain modulation deficits predict future development or severity of chronic pain in ME/CFS populations?
- What specific mechanisms explain the overlap in pain modulation abnormalities across different chronic pain syndromes—are they shared pathways or convergent dysfunction?
What This Study Does Not Prove
This review does not prove that abnormal pain modulation causes ME/CFS, only that it is associated with many chronic pain conditions. It is a mechanistic overview, not a prospective study, so it cannot establish whether defective pain inhibition predicts future disease development or severity in any specific population. The reliance on indirect evidence means definitive causal pathways remain unconfirmed.
Tags
Symptom:Pain
Biomarker:Neuroimaging
Metadata
- DOI
- 10.1586/ern.12.41
- PMID
- 22550986
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →